Patients & Families

At Gamida Cell, we are working tirelessly to apply innovation to meet the medical needs of patients. Through our efforts, we aim to enable more patients with blood cancers and rare, serious blood disorders to reach a cure.

We are currently conducting multiple clinical trials of our investigational, advanced cellular therapies, omidubicel1 and GDA-201:

  • Phase 3 study of omidubicel in patients with high-risk hematologic malignancies, including leukemia, lymphoma and myelodysplastic syndrome, who need a bone marrow transplant but do not have a suitable matched donor (clinicaltrials.gov NCT02730299).
  • An investigator-sponsored Phase 1/2 study of omidubicel in patients with severe aplastic anemia2 (clinicaltrials.gov NCT03173937).
  • An investigator-sponsored Phase 1 study of GDA-201 in combination with antibodies in adult patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma (clinicaltrials.gov NCT03019666).

For more information about these trials, visit the clinicaltrials.gov links above or contact us at medicalinformation@gamida-cell.com.

Gamida Cell is also proud to be working alongside advocacy organizations to serve the patient community. We invite you to visit the websites below for additional resources:

Be the Match
Leukemia & Lymphoma Society
Lymphoma Research Foundation
National Bone Marrow Transplant Link
BMT Infonet
The Aplastic Anemia and MDS International Foundation

Omidubicel and GDA-201 are investigational therapies, and their safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

1 Gamida Cell’s lead development candidate consists of omidubicel (expanded hematopoietic stem cells) and differentiated immune cells, including T cells. Gamida Cell refers to the two components collectively as “omidubicel.”
2 The Aplastic Anemia Investigational New Drug (IND) application is currently filed with the FDA under the brand name, CordIn, which is the same investigational development candidate as omidubicel.